approved EB-2 (NIW)

Scientist-I

Medicinal Chemistry · India · 2025-01-29

Processing Time
94 days
Decision Date
2025-01-29
Location
Wisconsin
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to investigate the design, synthesis, optimization, and characterization of small molecule compounds. This work focuses on developing therapeutic agents to address drug-resistant infections and improve medication safety and efficacy.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor addresses urgent healthcare challenges including drug-resistant infections and drug safety.

2 Well Positioned to Advance the Endeavor Met

The petitioner's Ph.D., 22 publications, and 547 citations demonstrate his ability to produce impactful research.

3 Balance of Factors Met

The petitioner's record of original research and capacity to advance drug discovery makes a waiver beneficial to the U.S.

Why This Petition Was Approved

The petition was approved based on the petitioner's Ph.D. in chemical sciences and a record of 22 peer-reviewed journal articles, 2 abstracts, and 1 granted patent. His work has garnered 547 citations and he has completed 24 peer-reviewed assignments, satisfying all three Dhanasar prongs.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Patents
Reference Letters Dependent
Grants
Judging Experience
Original Contributions
Government Alignment

Similar Cases

Research Assistant

Pharmaceuticals · China

WeGreened EB-2 (NIW) approved
California 426 days 2025-01-08
The petitioner proposes to continue research in pharmaceutical chemistry with a focus on drug discovery optimization and the development of advanced computational techniques. This work involves identifying new therapeutics for human diseases and creating computational methods that offer significant advantages over conventional drug discovery approaches. The intended impact is to reduce the economic and social costs of disease while improving global public health.

Scientist

Pharmaceuticals · Bangladesh

WeGreened EB-2 (NIW) approved
Massachusetts 69 days 2022-04-19
The petitioner proposes to continue analyzing synthetic routes to isolate, synthesize, design, and ensure the safety of novel drug molecules. This work is part of innovative drug discovery projects aimed at treating cancer, heart disease, and infectious diseases to improve global and U.S. healthcare outcomes.

Others

Pharmaceuticals · South Korea

WeGreened EB-2 (NIW) approved
54 days 2025-03-24
The petitioner proposes to continue her research in pharmaceutical science by integrating advanced technologies and computational approaches to develop novel drug candidates. Her work focuses on improving drug delivery systems to create more effective, affordable, and stable medications for chronic diseases including cancer, diabetes, hypertension, and neurodegenerative diseases.

Research Scientist

Pharmaceuticals · China

WeGreened EB-2 (NIW) approved
Utah 52 days 2025-03-07
The petitioner proposes to design and develop novel antimicrobial compounds for in vitro and in vivo applications to combat resistant pathogens and bridge the gap between basic discovery and clinical translation.

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-01-29.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 94 days
Criteria Met 3 / 3
Evidence Types 8

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,813
Success Rate 53.7%
Sustained 2,046
Dismissed 1,671

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist